YUNGJIN PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,130 KRW | -0.47% |
|
+0.71% | +0.24% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2008 | 111B 81.82M | Sales 2009 | 103B 76.29M | Capitalization | 145B 107M |
|---|---|---|---|---|---|
| Net income 2008 | -6.73B -4.97M | Net income 2009 | -4.35B -3.21M | EV / Sales 2008 | 1.15 x |
| Net Debt 2008 | 34.9B 25.76M | Net Debt 2009 | 46.26B 34.14M | EV / Sales 2009 | 1.85 x |
| P/E ratio 2008 |
-13.7
x | P/E ratio 2009 |
-33.5
x | Employees | 574 |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 47.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.47% | ||
| 1 week | +0.71% | ||
| Current month | +0.71% | ||
| 1 month | +5.71% | ||
| 3 months | +4.67% | ||
| 6 months | -4.48% | ||
| Current year | +0.24% |
1 week
2 075.00
2 175.00
1 month
2 015.002 240.00
Current year
2 000.002 290.00
1 year
1 960.002 995.00
3 years
1 960.006 450.00
5 years
1 960.0012 800.00
10 years
1 255.0019 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gi-Soo Lee
CEO | Chief Executive Officer | 58 | 22-03-23 |
Hyo-Jin Oh
BRD | Director/Board Member | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Joon Song
BRD | Director/Board Member | 54 | 17-03-23 |
Hyo-Jin Oh
BRD | Director/Board Member | 52 | - |
Gi-Soo Lee
CEO | Chief Executive Officer | 58 | 22-03-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2,130 | -0.47% | 69,300 |
| 24-05-16 | 2,140 | +1.42% | 273,884 |
| 24-05-14 | 2,110 | +0.96% | 134,731 |
| 24-05-13 | 2,090 | -1.18% | 198,611 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
Yungjin Pharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The Company also engages in the leasing of real estates.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.24% | 288M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- A003520 Stock
